<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        74-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KEPAM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        562.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Kepam</strong> is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).</p><p><strong>Kepam</strong> contains the active substance Levetiracetam , it is used:</p><p>&bull; on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy.</p><p>Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).</p><p>Levetiracetam has been given to you by your doctor to reduce the number of fits.</p><p>&bull; as an add-on to other antiepileptic medicines to treat:</p><p>&bull; partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age</p><p>&bull; myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.</p><p>&bull; primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).</p><p>Levetiracetam solution is an alternative for patients when administration of the antiepileptic oral levetiracetam medicine is temporarily not feasible.</p><p dir="RTL">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Kepam</strong></p><p>&bull; if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before you are given Levetiracetam solution, if you:</p><p>&bull; suffer from kidney problems, follow your doctor&rsquo;s instructions.</p><p>He/she may decide if your dose should be adjusted.</p><p>&bull; notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor.</p><p>&bull; a small number of people being treated with anti-epileptics such as Levetiracetam solution have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.</p><p><strong>Children and adolescents</strong></p><p>&bull; Levetiracetam solution is not indicated in children and adolescents below 16 years on it&rsquo;s own (monotherapy)</p><p><strong>Other medicines and levetiracetam</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Levetiracetam solution should not be used during pregnancy unless clearly necessary. A risk of birth defects for your unborn child cannot be completely excluded. Levetiracetam solution has shown unwanted reproductive effects in animal studies at dose levels higher than you would need to control your seizures.</p><p>Breast-feeding is not recommended during treatment.</p><p><strong>Driving and using machines</strong></p><p>Levetiracetam solution may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose.</p><p>You should not drive or use machines until it is established that your ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A doctor or a nurse will administer you Levetiracetam as an intravenous infusion.</p><p>Levetiracetam solution must be administered twice a day, once in the morning and once in the evening, at about the same time each day.</p><p>The intravenous formulation is an alternative to your oral administration. You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. Your total daily dose and frequency of administration remain identical.</p><p><strong>Monotherapy</strong></p><p><strong>Dose in adults and adolescents (from 16 years of age):</strong></p><p>General dose: between 1000 mg and 3,000 mg each day.</p><p>When you are first start given Levetiracetam solution, your doctor will prescribe you a lower dose during</p><p>2 weeks before giving you the lowest general dose.</p><p><strong>Add-on therapy</strong></p><p><strong>Dose in adults and adolescents (12 to 17 years) weighing</strong></p><p><strong>50 kg or more:</strong></p><p>General dose: between 1,000 mg and 3,000 mg each day.</p><p><strong>Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:</strong></p><p>General dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day .</p><p><strong>Method and route of administration:</strong></p><p>Levetiracetam solution is for intravenous use.</p><p>The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15-minutes.</p><p>For doctors and nurses, more detailed direction for the proper use of Levetiracetam solution is provided in section 6.</p><p><strong>Duration of treatment:</strong></p><p>&bull; There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.</p><p><strong>If you stop using </strong><strong>Kepam </strong><strong>:</strong></p><p>If stopping treatment, as with other antiepileptic medicines,</p><p>Levetiracetam solution should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Levetiracetam solution treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam solution.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor immediately, or go to your nearest emergency department, if you experience:</strong></p><p>&bull; suicide attempt and suicidal ideation</p><p>&bull; rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese</p><p>patients</p><p>&bull; weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction</p><p>&bull; swelling of the face, lips, tongue and throat (Quincke&rsquo;s oedema)</p><p>&bull; flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms DRESS)</p><p>&bull; symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function</p><p>&bull; a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)</p><p>&bull; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)</p><p>&bull; a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)</p><p>&bull; signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behavior or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.</p><p>The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common.</p><p>These effects should however decrease over time.</p><p><strong>Very common: </strong>may affect more than 1 user in 10 people</p><p>&bull; nasopharyngitis;</p><p dir="RTL">&bull; headache.</p><p><strong>Common: </strong>may affect 1 to 10 users in 100 people</p><p>&bull; anorexia (loss of appetite);</p><p>&bull; depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;</p><p>&bull; convulsion, dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm);</p><p>&bull; balance disorder (equilibrium disorder);</p><p>&bull; vertigo (sensation of spinning);</p><p>&bull; cough;</p><p>&bull; abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;</p><p>&bull; rash;</p><p>&bull; asthenia/fatigue (tiredness).</p><p><strong>Uncommon: </strong>may affect 1 to 10 users in 1000 people</p><p>&bull; decreased number of blood platelets, decreased number of white blood cells;</p><p>&bull; weight decrease, weight increase;</p><p>&bull; mental disorder, hallucination, anger, panic attack, emotional instability/mood swings, agitation;</p><p>&bull; abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);</p><p>&bull; diplopia (double vision), vision blurred;</p><p>&bull; elevated/abnormal values in a liver function test;</p><p>&bull; hair loss, eczema, pruritus;</p><p>&bull; muscle weakness, myalgia (muscle pain);</p><p>&bull; injury.</p><p><strong>Rare: </strong>may affect 1 to 10 users in 10,000 people</p><p>&bull; infection;</p><p>&bull; decreased number of all blood cell types;</p><p>&bull; decreased blood sodium concentration;</p><p>&bull; suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);</p><p>&bull; uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);</p><p>&bull; pancreatitis;</p><p>&bull; liver failure, hepatitis;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use this medicine after the expiry date stated on the vial and carton box after EXP:. The expiry date refers to the last day of the month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.What Levetiracetam solution contains</strong></p><p>The active substance is called levetiracetam.</p><p>Each ml contains 100 mg of levetiracetam.</p><p>The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Levetiracetam solution (sterile concentrate) is a clear, colourless liquid.
Levetiracetam solution is packed in a cardboard box containing 10 vials of 5 ml.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Jordan,</p><p>King Abdullah II Industrial Estate,</p><p>Amman &ndash; Jordan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oct-19
MP3020307	

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">كيبام هو دواء مضاد للصرع (يستخدم في علاج نوبات الصرع).</p><p dir="RTL">يحتوي كيبام على المادة الفعالة ليفيتيراسيتام ، وهي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعطى بمفردها للبالغين والمراهقين من سن 16 والذين تم تشخيصهم حديثًا بالإصابة بالصرع وذلك لعلاج حالات معينة من الصرع.</p><p dir="RTL">الصرع هو حالة يعاني فيها المرضى من النوبات المتكررة. يستعمل <strong>كيبام</strong> في علاج حالات النوبات الجزئية حيث تُصيب النوبات فقط في البداية جزء واحد من الدماغ (حالات النوبات الجزئية ولكن يمكن لها فيما بعد أن تُصيب أجزاء أكبر</p><p dir="RTL">فتشمل نصفي الدماغ مع أو بدون تعميم ثانوي). يوصف <strong>كيبام </strong>للحد من عدد نوبات الصرع.</p><p dir="RTL">فهو بمثابة علاج إضافي على الأدوية المضادة للصرع ويستعمل في علاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات النوبات الجزئية مع أو بدون تعميم ثانوي والتي تحدث للبالغين وللمراهقين والأطفال من سن الرابعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبة الرَمَعِيَّة العضلية (تظهر كانقباضات عضلية فجائية قصيرة ولا إرادية تشمل كل الجسم أو جزءًا منه) ويحدث الصرع الرمعي العضلي اليفعي عند البالغين والمراهقين من سن 12.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبة التوترية الرَّمَعِيَّة الأولية (نوبة كبيرة تشمل فقدان الوعي) وتحدث عند البالغين والمراهقين من سن 12 ممن يعانون من الصرع المعمم مجهول السبب (والذي يعتقد بأن السبب فيه سبب وراثي). يستخدم محلول ليفيتيراسيتام كبديل للمرضى وذلك في حال عدم إمكانية تناول الأقراص بالفم المضادة للصرع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يمتنع تناول كيبام في الحالات التالية:</strong></p><p dir="RTL">إذا كانت لديك حساسية من ليفيتيراسيتام أو مشتقات البوفيدون أو أي من مكوناته الأخرى (المذكورة في الفقرة 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">قم بالتحدث مع طبيبك قبل تناول ليفيتيراسيتام في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلية يجب عليك إتباع تعليمات الطبيب وسيقرر حينها تغيير جرعتك من عدمه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أي بطء في النمو أو تطور مفاجئ فيما يتعلق بعملية البلوغ الخاص بطفلك، بالرجاء التواصل مع الطبيب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عانى عدد قليل من الأشخاص الذين عُولجوا بالأدوية المضادة للصرع كمحلول ليفيتيراسيتام من أفكار حول إلحاق الضرر بأنفسهم أو إنهاء حياتهم. إذا كانت لديك أي أعراض من أعراض الاكتئاب و/ أو راودتك أي أفكار انتحارية، بالرجاء التواصل مع الطبيب.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح للأطفال والمراهقين دون سن 16 بتناول محلول ليفيتيراسيتام بمفرده (كعلاج أحادي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعل كيبام مع الأدوية الأخرى</strong></p><p dir="RTL">أبلغ الطبيب أو الصيدليّ إذا كنت تتناول أو قد تناولت مؤخرًا أو تنوي تناول أي أدوية أخرى بما في ذلك الأدوية التي يتم صرفها</p><p dir="RTL">دون الحصول على وصفة طبية.</p><p dir="RTL">لا تتناول ماكروغول (دواء مُلين) قبل ساعة من تناولك ليفيتيراسيتام وبعد تناوله بساعة حيث أن من شأنه التقليل من فعالية الدواء.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب استشارة الطبيب قبل تناول هذا الدواء إذا كنت حاملًا أو مُرضع أو تخططين للحمل.</p><p dir="RTL">يجب تجنب تناول محلول ليفيتيراسيتام أثناء فترة الحمل إلا إذا وجدت حاجة ماسة لذلك.</p><p dir="RTL">لا يمكن الجزم بعدم تعرض جنينك للتشوهات الخلقية نتيجة تناولك لهذا الدواء. أظهرت الأبحاث التي أجريت على الحيوانات فيما يتعلق بمحلول ليفيتيراسيتام وجود تأثيرات غير مرغوب بها على الأجنّة وذلك عند رفع مستوى الجرعة بأعلى من المستوى المطلوب للسيطرة على النوبات.</p><p dir="RTL">لا يُنصح بالرضاعة الطبيعية أثناء فترة العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن لمحلول ليفيتيراسيتام التأثير على قدرتك على القيادة أو على استخدام أي أدوات أو آلات حيث أنه قد يُشعرك بالنعاس. ويحدث ذلك غالبًا في بداية العلاج أو بعد مضاعفة الجرعة.</p><p>ينبغي عليك الامتناع عن القيادة واستخدام الآلات حتى يتم التأكد من قدرتك على ممارسة تلك الأنشطة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يقوم الطبيب أو الممرض بحقن ليفيتيراسيتام عن طريق التسريب الوريدي. يُعطى محلول ليفيتيراسيتام مرتين يوميًا، مرة في الصباح ومرة في المساء في نفس الموعد كل يوم.</p><p dir="RTL">إن الحقن الوريدي هو بديل الأقراص بالفم. يمكنك التحول من الأقراص المغلفة أو من شراب المحلول إلى الحقن الوريدي</p><p dir="RTL">أو العكس مباشرة وبدون جرعة مخصوصة. ستظل الجرعة اليومية وعدد مرات تناول الدواء ثابتة بدون أي تغيير.</p><p dir="RTL"><strong>العلاج الأحادي</strong></p><p dir="RTL"><strong>الجرعة للبالغين والمراهقين (من سن 16سنة):</strong></p><p dir="RTL">الجرعة العامة: من 1000 ملغم إلى 3.000 ملغم كل يوم.</p><p dir="RTL">سيصف لك طبيبك عند بدئك بتناول محلول ليفيتيراسيتام، أقل جرعة ممكنة خلال أول أسبوعين لك من العلاج ومن ثم</p><p dir="RTL">سيصف لك أقل جرعة عامة.</p><p dir="RTL"><strong>العلاج الإضافي</strong></p><p dir="RTL"><strong>الجرعة الموصي بها للبالغين والمراهقين (من سن 12 إلى 17 سنة)</strong> <strong>بوزن 50 كيلوغرام أو أكثر:</strong></p><p dir="RTL">الجرعة العامة: من 1000 ملغم إلى 3.000 ملغم كل يوم.</p><p dir="RTL"><strong>الجرعة الموصى بها للأطفال (من سن 4 إلى 11سنة) وللمراهقين (من سن 12 إلى 17سنة)</strong> <strong>بوزن أقل من50 كيلوغرام:</strong></p><p dir="RTL">الجرعة العامة: من 20_60 ملغم لكل كيلوغرام من وزن الجسم في كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء هذا الدواء:</strong></p><p dir="RTL">إن محلول ليفيتيراسيتام هو محلول للاستعمال الوريدي.</p><p dir="RTL">لابد أن يتم تخفيف الجرعة الموصى بها (على الأقل 100 مل) باستخدام مادة التخفيف المناسبة مع التنقيط الوريدي لمدة تزيد عن 15 دقيقة.</p><p dir="RTL">توجد توجيهات مفصلة للأطباء والممرضين بشأن الاستخدام الصحيح لمحلول ليفيتيراسيتام في الفقرة 6.</p><p dir="RTL"><strong>مدة العلاج:</strong></p><p dir="RTL">لا توجد تجربة بشأن حقن محلول ليفيتيراسيتام لمدة تزيد عن 4 أيام.</p><p dir="RTL"><strong>عند التوقف عن أخذ كيبام :</strong></p><p dir="RTL">كما هو الحال مع باقي الأدوية المضادة للصرع، عند التوقف عن العلاج، لابد من التوقف التدريجي وذلك لمنع حدوث المزيد من النوبات. عندما يقرر طبيبك توقفك عن العلاج بمحلول ليفيتيراسيتام، فأنه سيعطي لك التعليمات الخاصة بالتقليل التدريجي لمحلول ليفيتيراسيتام.</p><p>يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضي</p><p dir="RTL"><strong>أخبر طبيبك على الفور أو قم بالذهاب إلى أقرب قسم طوارئ إذا واجهت أيّ من ذلك </strong></p><p dir="RTL">محاولة الانتحار أو التفكير فيه</p><p dir="RTL">انحلال البربيدات / العضلات (انهيار الأنسجة العضلية) وما يرتبط بها من زيادة الكرياتين الناقل للفوسفات في الدم انتشار أعلى بكثير في المرضى اليابانيين بالمقارنة مع المرضى غير اليابانيين</p><p dir="RTL">&bull; الضعف أو الشعور بدوار خفيف أو بالدوار أو صعوبة في التنفس حيث قد تكون هذ علامات رد فعل (تحسسي شديد)</p><p dir="RTL">&bull; تورم في الوجه أو الشفاه أو اللسان أو الحلق (وذمة كوينيكس)</p><p dir="RTL">&bull; أعراض شبيهة بالإنفلونزا وطفح على الوجه متبوعًا بطفح جلدي ممتد بدرجة حرارة عالية وزيادة مستويات إنزيمات الكبد التي تظهر في فحوصات الدم وزيادة في نوع من كرات الدم البيضاء (كثرة اليوزينيات) والغدد الليمفاوية المتضخمة (التفاعل الدوائي مع كثرة اليوزينيات والأعراض الجهازية)</p><p dir="RTL">&bull; أعراض مثل قلة البول والتعب والغيثان والقيئ والارتباك والتورم في الساقين والكاحلين أو القدمين، حيث قد يكون علامة على انخفاض مفاجئ في وظائف الكلى</p><p dir="RTL">&bull; طفح جلدي قد يشكل بثورًا ويبدو وكأنه أهداف صغيرة (بقع داكنة مركزية محاطة بمنطقة شاحبة، مع حلقة داكنة حول الحافة) (احمرار الجلد متعدد الأشكال)</p><p dir="RTL">&bull; طفح جلدي مع انتشار البثور وتقشر الجلد خاصة حول الفم والأنف والعينين والأعضاء التناسلية (متلازمة ستيفنس جونسون)</p><p dir="RTL">&bull; شكل أكثر حدة من الطفح الجلدي يسبب تقشير الجلد في أكثر من 30 ٪ من سطح الجسم (تحلل سام للبشرة)</p><p dir="RTL">&bull; علامات تغيرات عقلية خطيرة أو إذا لاحظ شخص من حولك علامات الارتباك أو النعاس (الاستلقاء) أو النسيان (فقدان الذاكرة) أو ضعف الذاكرة (السهو) أو السلوك غير الطبيعي</p><p dir="RTL">أو العلامات العصبية الأخرى بما في ذلك الحركات اللاإرادية أو العشوائية. وقد تكون هذه أعراض الاعتلال الدماغي.</p><p dir="RTL"><strong>تعتبر ردود الفعل للآثار الجانبية الأكثر شيوعًا هي </strong></p><p dir="RTL">التهاب البلعوم والاستلقاء (النعاس) والإرهاق والصداع والدوار. في بداية العلاج أو عند زيادة الجرعة قد تكون الآثار الجانبية مثل النعاس والتعب والدوخة أكثر شيوعًا. يجب أن تنخفض هذه الآثار مع مرور الوقت</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جداً:</strong> التي قد تؤثر في أكثر من مستخدم 1 من بين 10 أشخاص</p><p dir="RTL">&bull; التهاب البلعوم الأنفي</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة: التي قد تؤثر في 10 من بين 100 أشخاص</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; الاكتئاب والعداء أو العدوان والقلق والأرق والعصبية أو التهيج</p><p dir="RTL">&bull; التشنج والدوار (الإحساس بعدم الثبات) والخمول (الإرهاق وفقدان الحماس)</p><p dir="RTL">&bull; اضطراب في القدرة على الاتزان (اضطراب التوازن)</p><p dir="RTL">&bull; الدوار (شعور بالدوار)</p><p dir="RTL">&bull; سعال</p><p dir="RTL">&bull; ألم في البطن وإسهال وعسر الهضم والغثيان والقيئ</p><p dir="RTL">&bull; طفح جلدي</p><p dir="RTL">&bull; الوهن/ الإرهاق (التعب).</p><p dir="RTL"><strong>الآثار الجانبية الغير مألوفة:</strong> التي قد تؤثر في 1 إلى 10 من بين 1000 أشخاص</p><p dir="RTL">&bull; نقص في عدد الصفائح الدموية في الدم ونقص عدد كرات الدم البيضاء</p><p dir="RTL">&bull; نقص أو زيادة الوزن</p><p dir="RTL">&bull;الاضطراب العقلي والهلوسة والغضب ونوبات الهلع وعدم الاستقرار النفسي/ تقلب المزاج والإثارة</p><p dir="RTL">&bull; تنسيق غير طبيعي/ الترنّح (حركات منسقة ضعيفة). الشعور بالوخز (التنميل) اضطراب في القدرة علي التنبيه (فقدان التركيز)</p><p dir="RTL">&bull; (ازدواج الرؤية) أو تشوش الرؤية</p><p dir="RTL">&bull; القيم المرتفعة/ الغير طبيعية في اختبار وظائف الكبد</p><p dir="RTL">&bull; تساقط الشعر والإكزيما والشعور بالحكة</p><p dir="RTL">&bull; ضعف في العضلات وألم عضلي (ألم في العضلات)</p><p dir="RTL">&bull; الإصابة.</p><p dir="RTL"><strong>الآثار الجانبية النادرة:</strong> التي قد تؤثر في 1 إلى 10 من بين 10,000 أشخاص</p><p dir="RTL">عدوى</p><p dir="RTL">نقص عدد كرات الدم المتنوعة</p><p dir="RTL">نقص مستوي تركيز الصوديوم في الدم</p><p dir="RTL">&bull; الانتحار أو اضطرابات الشخصية (المشكلات السلوكية) التفكير غير الطبيعي (التفكير البطيء وعدم القدرة على التركيز) تشنجات عضلية لا يمكن السيطرة عليها تؤثر على الرأس والجذع والأطراف وصعوبة التحكم في الحركات وفرط الحركة (فرط الحركة)</p><p dir="RTL">&bull; التهاب في البنكرياس، فشل كبدي والتهاب في الكبد</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">يجب عدم تخزينها في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على العبوة بعد الانتهاء كما يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير&nbsp; في الشهر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>6 محتويات العبوّة ومعلومات إضافية</strong></p><p dir="RTL"><strong>أ.ما يحتويه كيبام</strong></p><p dir="RTL">المادة الفعالة: تسمي لفيتيراسيتام، يحتوي كل مل على 100ملغم من ليفيتيراسيتام.</p><p dir="RTL">المكونات الأخرى هي: أسيتات الصوديوم ثلاثي الهيدرات وحمض الأسيتيك الثلجي وكلوريد الصوديوم، ماء للحقن وكلوريد الصوديوم وماء للحقن</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول ليفيتيراسيتام (مركز معقم) هو سائل صافٍ عديم اللون. يتم تعبئة محلول ليفيتيراسيتام في صندوق من الورق المقوى ، وتأتي في 10 عبوات وحجم العبوة الواحدة 5 مل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ام اس فارما - الأردن ذ.م.م ،</p><p dir="RTL">مدينة الملك عبداله الثاني الصناعية</p><p dir="RTL">عمان - الأردن</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Oct-19
MP3020307

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kepam 500mg/5ml solution for Infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial contains 500mg of Levetiracetam as active substance . 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Infusion. 
Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1 Therapeutic indications</strong></p><p>Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</p><p>Levetiracetam is indicated as adjunctive therapy</p><p>&bull; in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.</p><p>&bull; in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</p><p>&bull; in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.</p><p>Levetiracetam concentrate for solution for infusion is an alternative for patients when oral administration is temporarily not feasible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.2 Posology and method of administration</strong></p><p><u>Posology</u></p><p>Levetiracetam therapy can be initiated with either intravenous or oral administration.</p><p>Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained.</p><p><em>Monotherapy for adults and adolescents from 16 years of age</em></p><p>The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.</p><p><em>Add-on therapy for adults (&ge;18 years) and adolescents (12 to 17 years) weighing 50 kg or more</em></p><p>The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.</p><p><u>Duration of treatment</u></p><p>There is no experience with administration of intravenous Levetiracetam for longer period than 4 days.</p><p><u>Discontinuation</u></p><p>If Levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).</p><p><u>Special populations</u></p><p><em>Elderly (65 years and older)</em></p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function (see &ldquo;Renal impairment&rdquo; below).</p><p><em>Renal impairment</em></p><p>The daily dose must be individualised according to renal function.</p><p>For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighting 50 kg or more, the following formula:</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_8" o:spid="_x0000_i1027" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE1.PNG"
 style='width:327pt;height:39pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="spc~37007~1~IMAGE1"/>
</v:shape><![endif]--><img width="436" height="52" alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE1.PNG" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p>Then CLcr is adjusted for body surface area (BSA) as follows:</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_6" o:spid="_x0000_i1026" type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE2.PNG"
 style='width:261pt;height:39pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif"
  o:title="spc~37007~1~IMAGE2"/>
</v:shape><![endif]--><img width="348" height="52" alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE2.PNG" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Dosing adjustment for adult and adolescents patients weighing more than 50 kg with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Group</p></td><td style="vertical-align:top"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p><p>Mild</p><p>Moderate</p><p>Severe</p><p>End-stage renal disease patients undergoing dialysis&nbsp;<sup>(1)</sup></p></td><td style="vertical-align:top"><p>&gt; 80</p><p>50-79</p><p>30-49</p><p>&lt; 30</p><p>-</p></td><td style="vertical-align:top"><p>500 to 1,500 mg twice daily</p><p>500 to 1,000 mg twice daily</p><p>250 to 750 mg twice daily</p><p>250 to 500 mg twice daily</p><p>500 to 1,000 mg once daily&nbsp;<sup>(2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup>&nbsp;A 750 mg loading dose is recommended on the first day of treatment with Levetiracetam.</p><p><sup>(2)</sup>&nbsp;Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, Levetiracetam dose needs to be adjusted based on the renal function as Levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.</p><p>The CLcr in ml/min/1.73 m<sup>2</sup>&nbsp;may be estimated from serum creatinine (mg/dl) determination, for young adolescents and children using the following formula (Schwartz formula):</p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE3.PNG"
 style='width:249pt;height:39pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif"
  o:title="spc~37007~1~IMAGE3"/>
</v:shape><![endif]--><img width="332" height="52" alt="https://www.medicines.org.uk/emc/images/spc/spc~37007~1~IMAGE3.PNG" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></p><p>ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male</p><p>Dosing adjustment for children and adolescents patients weighing less than 50 kg with impaired renal function</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Group</p></td><td rowspan="2" style="vertical-align:top"><p>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>Dose and frequency</p></td></tr><tr><td style="vertical-align:top"><p>Children from 4 years and adolescents weighing less than 50 kg</p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&gt; 80</p></td><td style="vertical-align:top"><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease patients undergoing dialysis</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily&nbsp;<sup>(1) (2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup>&nbsp;A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with Levetiracetam.</p><p><sup>(2)</sup>&nbsp;Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m<sup>2</sup>.</p><p><u>Paediatric population</u></p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.</p><p><em>Monotherapy</em></p><p>The safety and efficacy of Levetiracetam in children below and adolescents 16 years as monotherapy treatment have not been established.</p><p>No data are available.</p><p><em>Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg</em></p><p>The initial therapeutic dose is 10 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.</p><p>Dose in children 50 kg or greater is the same as in adults.</p><p>Dose recommendations for children and adolescents:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Starting dose:</p><p>10 mg/kg twice daily</p></td><td style="vertical-align:top"><p>Maximum dose:</p><p>30 mg/kg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>15 kg&nbsp;<sup>(1)</sup></p></td><td style="vertical-align:top"><p>150 mg twice daily</p></td><td style="vertical-align:top"><p>450 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>20 kg&nbsp;<sup>(1)</sup></p></td><td style="vertical-align:top"><p>200 mg twice daily</p></td><td style="vertical-align:top"><p>600 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>25 kg</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>From 50 kg&nbsp;<sup>(2)</sup></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1500 mg twice daily</p></td></tr></tbody></table><p><sup>(1)&nbsp;</sup>Children 25 kg or less should preferably start the treatment with Levetiracetam 100 mg/ml oral solution.</p><p><sup>(2)&nbsp;</sup>Dose in children and adolescents 50 kg or more is the same as in adults.</p><p><em>Add-on therapy for infants and children less than 4 years</em></p><p>The safety and efficacy of Levetiracetam concentrate for solution for infusion in infants and children less than 4 years have not been established.</p><p>Currently available data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be made.</p><p><u>Method of administration</u></p><p>Levetiracetam concentrate for solution for infusion is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.4 Special warnings and precautions for use</strong></p><p><u>Renal impairment</u></p><p>The administration of Levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2).</p><p><u>Acute kidney injury</u></p><p>The use of Levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.</p><p><u>Blood cell counts</u></p><p>Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with Levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (section 4.8).</p><p><u>Suicide</u></p><p>Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including Levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.</p><p>Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.</p><p><u>Paediatric population</u></p><p>Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Antiepileptic medicinal products</u></p><p>Pre-marketing data from clinical studies conducted in adults indicate that Levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Levetiracetam.</p><p>As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day Levetiracetam.</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered Levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher Levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><u>Probenecid</u></p><p>Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of Levetiracetam. Nevertheless, the concentration of this metabolite remains low.</p><p><u>Methotrexate</u></p><p>Concomitant administration of Levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and Levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs</p><p><u>Oral contraceptives and other pharmacokinetics interactions</u></p><p>Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of Levetiracetam.</p><p><u>Alcohol</u></p><p>No data on the interaction of Levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Postmarketing data from several prospective pregnancy registries have documented outcomes in over 1000 women exposed to Levetiracetam monotherapy during the first trimester of pregnancy. Overall, these data do not suggest a substantial increase in the risk for major congenital malformations, although a teratogenic risk cannot be completely excluded. Therapy with multiple antiepileptic medicinal products is associated with a higher risk of congenital malformations than monotherapy and, therefore, monotherapy should be considered. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>Levetiracetam is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.</p><p>Physiological changes during pregnancy may affect Levetiracetam concentration. Decrease in Levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with Levetiracetam should be ensured. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus.</p><p><u>Breast-feeding</u></p><p>Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.</p><p>However, if Levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breastfeeding.</p><p><u>Fertility</u></p><p>No impact on fertility was detected in animal studies (see section 5.3). No clinical data are available, potential risk for human is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks,&nbsp;<em>e.g</em>. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with Levetiracetam. These data are supplemented with the use of Levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of Levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications. Since there was limited exposure for Levetiracetam intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of Levetiracetam intravenous will rely on Levetiracetam oral use.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in clinical studies (adults, adolescents, children and infants &gt; 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2"><p><strong>MedDRA SOC</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia, leukopenia</p></td><td style="vertical-align:top"><p>Pancytopenia,neutropenia, agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Weight decreased, weight increase</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Depression, hostility/ aggression, anxiety, insomnia, nervousness/irritability</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation</p></td><td style="vertical-align:top"><p>Completed suicide, personality disorder, thinking abnormal</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Somnolence, headache</p></td><td style="vertical-align:top"><p>Convulsion, balance disorder, dizziness, lethargy, tremor</p></td><td style="vertical-align:top"><p>Amnesia, memory impairment, coordination abnormal/ataxia, paraesthesia, disturbance in attention</p></td><td style="vertical-align:top"><p>Choreoathetosis, dyskinesia, hyperkinesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diplopia, vision blurred</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Abdominal pain, diarrhoea, dyspepsia, vomiting, nausea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute kidney injury</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Alopecia, eczema, pruritus,</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscular weakness, myalgia</p></td><td style="vertical-align:top"><p>Rhabdomyolysis and blood creatine phosphokinase increased*</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia/fatigue</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Injury</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p>Cases of encephalopathy have been rarely observed after Levetiracetam administration. These undesirable effects generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.</p><p><u>Description of selected adverse reactions</u></p><p>The risk of anorexia is higher when Levetiracetam is coadministered with topiramate.</p><p>In several cases of alopecia, recovery was observed when Levetiracetam was discontinued.</p><p>Bone marrow suppression was identified in some of the cases of pancytopenia.</p><p><u>Paediatric population</u></p><p>In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with Levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were treated with Levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with Levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with Levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of Levetiracetam.</p><p>In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for Levetiracetam were identified for infants less than 12 months of age with epilepsy.</p><p>The adverse reaction profile of Levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of Levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.</p><p>A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of Levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that Levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in Levetiracetam treated patients on aggressive behavior as measured in a standardized and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist). However subjects, who took Levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behavior were not worse than baseline.</p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.6pt;margin-top:5.95pt;width:375.05pt;height:99.6pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right dir=RTL style='text-align:left;mso-layout-grid-align:
    none;text-autospace:none'><span dir=LTR style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>National Pharmacovigilance and Drug
    Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax: +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Call NPC
    at +966-11-2038222</span> <span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>SFDA Call
    Center: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    class=MsoHyperlink><span style='font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;text-decoration:none;text-underline:
    none'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=LTR></span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail:
    </span><a href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></span></p>
    <p class=MsoListParagraphCxSpLast style='text-indent:-.25in;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="139" alt="Text Box: National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222 
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa

" src="file:///C:/Users/HIND~1.ALS/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Levetiracetam overdoses.</p><p><u>Management of overdose</u></p><p>There is no specific antidote for Levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for Levetiracetam and 74 % for the primary metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.</p><p>The active substance, Levetiracetam, is a pyrrolidone derivative (S-enantiomer of &alpha;-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p><u>Mechanism of action</u></p><p>The mechanism of action of Levetiracetam still remains to be fully elucidated.&nbsp;<em>In vitro</em>&nbsp;and&nbsp;<em>in vivo&nbsp;</em>experiments suggest that Levetiracetam does not alter basic cell characteristics and normal neurotransmission.</p><p><em>In vitro</em>&nbsp;studies show that Levetiracetam affects intraneuronal Ca<sup>2+</sup>&nbsp;levels by partial inhibition of N-type Ca<sup>2+</sup>&nbsp;currents and by reducing the release of Ca<sup>2+</sup>&nbsp;from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;-carbolines. Furthermore, Levetiracetam has been shown in&nbsp;<em>in vitro</em>&nbsp;studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between Levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><u>Pharmacodynamic effects</u></p><p>Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.</p><p>In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of Levetiracetam.</p><p><u>Clinical efficacy and safety</u></p><p><em>Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy:</em></p><p>In adults, Levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1000 mg, 2000 mg, or 3000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg Levetiracetam respectively and of 12.6 % for patients on placebo.</p><p><u>Paediatric population</u></p><p>In paediatric patients (4 to 16 years of age), Levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received Levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).</p><p>44.6 % of the Levetiracetam treated patients and 19.6 % of the patients on placebo had a 50 % or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure-free for at least 1 year.</p><p>35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged &lt; 6 months.</p><p><em>Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.</em></p><p>Efficacy of Levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400 &ndash; 1200 mg/day or Levetiracetam 1000 &ndash; 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.</p><p>Six-month seizure freedom was achieved in 73.0 % of Levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). More than half of the subjects remained seizure free for 12 months (56.6 % and 58.5 % of subjects on Levetiracetam and on carbamazepine CR respectively).</p><p>In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to Levetiracetam adjunctive therapy (36 adult patients out of 69).</p><p><em>Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.</em></p><p>Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy.</p><p>In this study, Levetiracetam, dose was 3000 mg/day given in 2 divided doses.</p><p>58.3 % of the Levetiracetam treated patients and 23.3 % of the patients on placebo had at least a 50 % reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.</p><p><em>Adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.</em></p><p>Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, Levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.</p><p>72.2 % of the Levetiracetam treated patients and 45.2 % of the patients on placebo had a 50 % or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4 % of the patients were free of tonic-clonic seizures for at least 6 months and 31.5 % were free of tonic-clonic seizures for at least 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic profile has been characterized following oral administration. A single dose of 1500 mg Levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1500 mg Levetiracetam oral intake, given as three 500 mg tablets.</p><p>The intravenous administration of doses up to 4000 mg diluted in 100 ml of 0.9 % sodium chloride infused over 15 minutes and doses up to 2500 mg diluted in 100 ml of 0.9 % sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.</p><p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of Levetiracetam was also confirmed following 1500 mg intravenous infusion for 4 days with twice daily dosing.</p><p>There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p><u>Adults and adolescents</u></p><p><u>Distribution</u></p><p>Peak plasma concentration (Cmax) observed in 17 subjects following a single intravenous dose of 1500 mg infused over 15 minutes was 51 &plusmn; 19 &micro;g/ml (arithmetic average &plusmn; standard deviation).</p><p>No tissue distribution data are available in humans.</p><p>Neither Levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10 %).</p><p>The volume of distribution of Levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p><u>Biotransformation</u></p><p>Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P<sub>450</sub>&nbsp;isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose).</p><p>Other unidentified components accounted only for 0.6 % of the dose.</p><p>No enantiomeric interconversion was evidenced&nbsp;<em>in vivo</em>&nbsp;for either Levetiracetam or its primary metabolite.</p><p><em>In vitro</em>, Levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P<sub>450</sub>&nbsp;isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, Levetiracetam does not affect the&nbsp;<em>in vitro</em>&nbsp;glucuronidation of valproic acid.</p><p>In human hepatocytes in culture, Levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and&nbsp;<em>in vivo</em>&nbsp;interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected&nbsp;<em>in vivo</em>. Therefore, the interaction of Levetiracetam with other substances, or&nbsp;<em>vice versa,</em>&nbsp;is unlikely</p><p><u>Elimination</u></p><p>The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.</p><p>The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion&nbsp;<em>via</em>&nbsp;faeces accounted for only 0.3 % of the dose.</p><p>The cumulative urinary excretion of Levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.</p><p>The renal clearance of Levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that Levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.</p><p><u>Elderly</u></p><p>In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population (see section 4.2).</p><p><u>Renal impairment</u></p><p>The apparent body clearance of both Levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).</p><p>In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.</p><p>The fractional removal of Levetiracetam was 51 % during a typical 4-hour dialysis session.</p><p><u>Hepatic impairment</u></p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of Levetiracetam. In most subjects with severe hepatic impairment, the clearance of Levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2).</p><p><u>Paediatric population</u></p><p><em>Children (4 to 12 years)</em></p><p>The pharmacokinetics in paediatric patients has not been investigated after intravenous administration. However, based on the pharmacokinetic characteristics of Levetiracetam, the pharmacokinetics in adults after intravenous administration and the pharmacokinetics in children after oral administration, the exposure (AUC) of Levetiracetam is expected to be similar in paediatric patients aged 4 to 12 years after intravenous and oral administration.</p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of Levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), Levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.</p><p>Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.</p><p>No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m2 or exposure basis) in parents and F1 generation.</p><p>Two embryo-fetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in fetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m2 basis) and 1200 mg/kg/day for fetuses.</p><p>Four embryo-fetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in fetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. The NOAEL was &lt;200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m2 basis).</p><p>A peri- and post-natal development study was performed in rats with Levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning.(x 6 the MRHD on a mg/m2 basis).</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6-17 the MRHD on a mg/m2 basis)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium acetate trihydrate</p><p>Glacial acetic acid</p><p>Sodium chloride</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Primary packaging :Vial 6R and Rubber Stopper 20mm</p><p>Secondary packaging: Carton. Insert and label</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>See Table 1 for the recommended preparation and administration of Levetiracetam concentrate for solution for infusion to achieve a total daily dose of 500 mg 1000 mg, 2000 mg, or 3000 mg in two divided doses.</p><p><u>Table 1. Preparation and administration of Levetiracetam concentrate&nbsp;</u>for solution for infusion</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Withdrawal Volume</strong></p></td><td style="vertical-align:top"><p><strong>Volume of Diluent</strong></p></td><td style="vertical-align:top"><p><strong>Infusion Time</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of administration</strong></p></td><td style="vertical-align:top"><p><strong>Total Daily Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>250 mg</p></td><td style="vertical-align:top"><p>2.5 ml(half5 ml vial)</p></td><td style="vertical-align:top"><p>100 ml</p></td><td style="vertical-align:top"><p>15 minutes</p></td><td style="vertical-align:top"><p>Twice daily</p></td><td style="vertical-align:top"><p>500 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>500 mg</p></td><td style="vertical-align:top"><p>5 ml(one5 ml vial)</p></td><td style="vertical-align:top"><p>100 ml</p></td><td style="vertical-align:top"><p>15 minutes</p></td><td style="vertical-align:top"><p>Twice daily</p></td><td style="vertical-align:top"><p>1000 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>1000 mg</p></td><td style="vertical-align:top"><p>10 ml(two5 ml vials)</p></td><td style="vertical-align:top"><p>100 ml</p></td><td style="vertical-align:top"><p>15 minutes</p></td><td style="vertical-align:top"><p>Twice daily</p></td><td style="vertical-align:top"><p>2000 mg/day</p></td></tr><tr><td style="vertical-align:top"><p>1500 mg</p></td><td style="vertical-align:top"><p>15 ml(three5 ml vials)</p></td><td style="vertical-align:top"><p>100 ml</p></td><td style="vertical-align:top"><p>15 minutes</p></td><td style="vertical-align:top"><p>Twice daily</p></td><td style="vertical-align:top"><p>3000 mg/day</p></td></tr></tbody></table><p>This medicinal product is for single use only, any unused solution should be discarded.</p><p>Levetiracetam concentrate for solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25 &deg;C.</p><p>Diluents:</p><p>&bull;Sodium chloride 9 mg/ml (0.9 %) solution for injection</p><p>&bull;Lactated Ringer&#39;s solution for injection</p><p>&bull;Dextrose 50 mg/ml (5 %) solution for injection</p><p>Medicinal product with particulate matter or discoloration should not be used.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct-19
SPC-047-00



            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>